Dexcom
Bridget Ruvalcaba is a seasoned financial professional currently serving as a Sr. Lead Financial Analyst at Dexcom since April 2023, focusing on R&D New Product Development Finance. Prior to this role, Bridget held various senior finance positions at Thermo Fisher Scientific, including Sr. Finance Manager for Global Shared Functions Finance and Manufacturing and Operations Finance. Experience at MSD as a Finance Specialist contributed to knowledge in the biotech sector. Bridget's earlier tenure at Thermo Fisher included multiple roles in finance and data analysis, supported by participation in the Financial Leadership Development Program. Education consists of a degree in Economics and Business Administration from the University of San Diego. Additionally, notable involvement in social issues includes work as a Human Trafficking Intern at the Trans-Border Institute, leading to published work and public speaking on modern-day slavery.
This person is not in any teams
Dexcom
45 followers
Founded in 1999, Dexcom, Inc. (NASDAQ: DXCM), is developing and marketing Continuous Glucose Monitoring (CGM) systems for ambulatory use by people with diabetes and by healthcare providers for the treatment of people with diabetes. The company is the leader in transforming diabetes care and management by providing CGM technology to help patients and healthcare professionals better manage diabetes.